BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Karpinski P, Rossowska J, Sasiadek MM. Immunological landscape of consensus clusters in colorectal cancer. Oncotarget 2017;8:105299-311. [PMID: 29285252 DOI: 10.18632/oncotarget.22169] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Hu LF, Lan HR, Huang D, Li XM, Jin KT. Personalized Immunotherapy in Colorectal Cancers: Where Do We Stand? Front Oncol 2021;11:769305. [PMID: 34888246 DOI: 10.3389/fonc.2021.769305] [Reference Citation Analysis]
2 Li X, Ling A, Kellgren TG, Lundholm M, Löfgren-Burström A, Zingmark C, Rutegård M, Ljuslinder I, Palmqvist R, Edin S. A Detailed Flow Cytometric Analysis of Immune Activity Profiles in Molecular Subtypes of Colorectal Cancer. Cancers (Basel) 2020;12:E3440. [PMID: 33228141 DOI: 10.3390/cancers12113440] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Menter DG, Davis JS, Broom BM, Overman MJ, Morris J, Kopetz S. Back to the Colorectal Cancer Consensus Molecular Subtype Future. Curr Gastroenterol Rep 2019;21:5. [PMID: 30701321 DOI: 10.1007/s11894-019-0674-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 6.7] [Reference Citation Analysis]
4 Zhu Z, Dong W. Overexpression of HHLA2, a member of the B7 family, is associated with worse survival in human colorectal carcinoma. Onco Targets Ther 2018;11:1563-70. [PMID: 29593422 DOI: 10.2147/OTT.S160493] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 4.8] [Reference Citation Analysis]
5 Du F, Liu Y. Predictive molecular markers for the treatment with immune checkpoint inhibitors in colorectal cancer. J Clin Lab Anal 2021;:e24141. [PMID: 34817097 DOI: 10.1002/jcla.24141] [Reference Citation Analysis]
6 Wu M, Wang Y, Liu H, Song J, Ding J. Genomic analysis and clinical implications of immune cell infiltration in gastric cancer. Biosci Rep 2020;40:BSR20193308. [PMID: 32338286 DOI: 10.1042/BSR20193308] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 Cohen R, Rousseau B, Vidal J, Colle R, Diaz LA Jr, André T. Immune Checkpoint Inhibition in Colorectal Cancer: Microsatellite Instability and Beyond. Target Oncol 2020;15:11-24. [PMID: 31786718 DOI: 10.1007/s11523-019-00690-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 14.0] [Reference Citation Analysis]
8 Galon J, Bruni D. The Role of the Immune Infiltrate in Distinct Cancer Types and Its Clinical Implications : Lymphocytic Infiltration in Colorectal Cancer. Cancer Treat Res 2020;180:197-211. [PMID: 32215871 DOI: 10.1007/978-3-030-38862-1_7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Ye L, Zhang T, Kang Z, Guo G, Sun Y, Lin K, Huang Q, Shi X, Ni Z, Ding N, Zhao KN, Chang W, Wang J, Lin F, Xue X. Tumor-Infiltrating Immune Cells Act as a Marker for Prognosis in Colorectal Cancer. Front Immunol 2019;10:2368. [PMID: 31681276 DOI: 10.3389/fimmu.2019.02368] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 14.3] [Reference Citation Analysis]
10 Fidelle M, Yonekura S, Picard M, Cogdill A, Hollebecque A, Roberti MP, Zitvogel L. Resolving the Paradox of Colon Cancer Through the Integration of Genetics, Immunology, and the Microbiota. Front Immunol 2020;11:600886. [PMID: 33381121 DOI: 10.3389/fimmu.2020.600886] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
11 Miller SA, Ghobashi AH, O'Hagan HM. Consensus molecular subtyping of colorectal cancers is influenced by goblet cell content. Cancer Genet 2021;254-255:34-9. [PMID: 33571895 DOI: 10.1016/j.cancergen.2021.01.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
12 Karpiński P, Łaczmański Ł, Sąsiadek MM. Major Histocompatibility Complex Genes as Therapeutic Opportunity for Immune Cold Molecular Cancer Subtypes. J Immunol Res 2020;2020:8758090. [PMID: 33282963 DOI: 10.1155/2020/8758090] [Reference Citation Analysis]
13 Bae JM, Yoo SY, Kim JH, Kang GH. Immune landscape and biomarkers for immuno-oncology in colorectal cancers. J Pathol Transl Med 2020;54:351-60. [PMID: 32580539 DOI: 10.4132/jptm.2020.05.15] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Kamal Y, Dwan D, Hoehn HJ, Sanz-Pamplona R, Alonso MH, Moreno V, Cheng C, Schell MJ, Kim Y, Felder SI, Rennert HS, Melas M, Lazaris C, Bonner JD, Siegel EM, Shibata D, Rennert G, Gruber SB, Frost HR, Amos CI, Schmit SL. Tumor immune infiltration estimated from gene expression profiles predicts colorectal cancer relapse. Oncoimmunology 2021;10:1862529. [PMID: 33763292 DOI: 10.1080/2162402X.2020.1862529] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Zhang J, Shen L, Deng Y, Sun X, Wang Y, Yao Y, Zhang H, Zou W, Zhang Z, Wan J, Yang L, Zhu J, Zhang Z. A novel LARCassigner3 classification predicts outcomes in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy: a retrospective training and validation analysis. Cancer Manag Res 2019;11:4153-70. [PMID: 31123421 DOI: 10.2147/CMAR.S196662] [Reference Citation Analysis]
16 Anderson P, Aptsiauri N, Ruiz-Cabello F, Garrido F. HLA class I loss in colorectal cancer: implications for immune escape and immunotherapy. Cell Mol Immunol 2021;18:556-65. [PMID: 33473191 DOI: 10.1038/s41423-021-00634-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
17 Xiong Y, Wang K, Zhou H, Peng L, You W, Fu Z. Profiles of immune infiltration in colorectal cancer and their clinical significant: A gene expression-based study. Cancer Med 2018;7:4496-508. [PMID: 30117315 DOI: 10.1002/cam4.1745] [Cited by in Crossref: 83] [Cited by in F6Publishing: 92] [Article Influence: 20.8] [Reference Citation Analysis]
18 Picard E, Verschoor CP, Ma GW, Pawelec G. Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer. Front Immunol 2020;11:369. [PMID: 32210966 DOI: 10.3389/fimmu.2020.00369] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 22.5] [Reference Citation Analysis]
19 Zaborowski AM, Winter DC, Lynch L. The therapeutic and prognostic implications of immunobiology in colorectal cancer: a review. Br J Cancer 2021. [PMID: 34302062 DOI: 10.1038/s41416-021-01475-x] [Reference Citation Analysis]
20 Requena DO, Garcia-Buitrago M. Molecular Insights Into Colorectal Carcinoma. Arch Med Res 2020;51:839-44. [PMID: 32962865 DOI: 10.1016/j.arcmed.2020.09.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Cohen R, Heran M, Pudlarz T, Hilmi M, Tournigand C, André T, Rousseau B. Traitement des cancers colorectaux par immunothérapie : aller au-delà de MSI avec la classification moléculaire (CMS) et la charge mutationnelle. Bulletin du Cancer 2019;106:151-61. [DOI: 10.1016/j.bulcan.2018.09.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
22 Ying Z, Shiue L, Park K, Kollet J, Bijani P, Goswami M, Duvic M, Ni X. Blood transcriptional profiling reveals IL-1 and integrin signaling pathways associated with clinical response to extracorporeal photopheresis in patients with leukemic cutaneous T-cell lymphoma. Oncotarget 2019;10:3183-97. [PMID: 31139332 DOI: 10.18632/oncotarget.26900] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
23 Marderstein AR, Uppal M, Verma A, Bhinder B, Tayyebi Z, Mezey J, Clark AG, Elemento O. Demographic and genetic factors influence the abundance of infiltrating immune cells in human tissues. Nat Commun 2020;11:2213. [PMID: 32371927 DOI: 10.1038/s41467-020-16097-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
24 Albuquerque C, Pebre Pereira L. Wnt Signalling-Targeted Therapy in the CMS2 Tumour Subtype: A New Paradigm in CRC Treatment? Adv Exp Med Biol 2018;1110:75-100. [PMID: 30623367 DOI: 10.1007/978-3-030-02771-1_6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
25 Zhuo Q, Yu B, Zhou J, Zhang J, Zhang R, Xie J, Wang Q, Zhao S. Lysates of Lactobacillus acidophilus combined with CTLA-4-blocking antibodies enhance antitumor immunity in a mouse colon cancer model.Sci Rep. 2019;9:20128. [PMID: 31882868 DOI: 10.1038/s41598-019-56661-y] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]